A $100 million Series D pushed the celebrity-backed women’s telehealth company past a $1 billion valuation, reflecting investor confidence in midlife care and as the global femtech market is expected to more than quadruple by 2035
Midi Health has crossed the $1 billion valuation threshold after raising $100 million in a Series D financing round, a milestone that places the women’s health platform among a small group of peers to reach unicorn status, such as Maven Clinic.
The round was led by Goodwater Capital, with new participation from Foresite Capital and Serena Ventures, alongside backing from existing investors Advance Venture Partners, Google Ventures, Emerson Collective, SemperVirens, McKesson Ventures and Felicis Ventures.
The Palo Alto-based startup counts Mount Sinai Health System as a partner in expanding menopause care across the New York City area, and even entered the supplement market with a line of products for women aged 35 to 65.
“This is validation for the movement we’re leading to provide women better healthcare,” Midi Health co-founder and CEO Joanna Strober said. “Women’s health has been treated like an afterthought for too long. This funding gives us the resources to rewrite that story at scale.”
Alongside the financing, Midi Health has bolstered its executive team, naming Jason Wheeler, formerly of Tesla, Google and Forward, as chief financial officer, Melissa Waters, previously at Meta, Lyft and Hims & Hers, as chief marketing officer and Matt Cook, most recently at Omada Health and Firefly Health, as chief commercial officer.
The funding follows a $50 million Series C round led by Advance Venture Partners (AVP) that occurred last year and an earlier SPV that included Amy Schumer, Connie Britton, Sheryl Sandberg, Tekedra Mawakana and Tory Burch among its backers.
Women’s health is drawing serious capital. A report from Astute Analytica projects the global femtech market will grow from $63 billion in 2025 to nearly $267 billion by 2035, a compound annual growth rate of more than 15%.
In recent weeks, several headlines have emerged across the space.
New Jersey-based VC firm FemHealth Ventures, which invests in drugs and tech in the women’s health space, recently closed its second fund at $65 million. Meanwhile, virtual maternity and women’s health company Pomelo Care raised $92 million in Series C funding at a $1.7 billion valuation, supporting its initiative to expand into additional life stages.
Joining Pomelo is Xella Health, a women’s health company that raised $3.7 million in pre-seed funding ahead of a launch this spring.
